TVTX Q1 2020 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+20.7% YoY

Gross Profit

$46M97.1% margin

Operating Income

-$15M-31.5% margin

Net Income

$808,0001.7% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$34M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$573M

Total Liabilities

$347M

Stockholders' Equity

$226M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$40M	+20.7%
Gross Profit	$46M	$39M	+20.4%
Operating Income	-$15M	-$38M	+60.6%
Net Income	$808,000	-$41M	+102.0%

Revenue Segments

Tiopronin Products

$25M53%

Bile Acid Products

$22M47%